Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Open, randomized, multicentric, controlled trial. Infants will be randomly allocated in one of the two study groups as follows:
Group A: 212 subjects will receive the PENTAXIM™ vaccine at 6, 10 and 14 weeks of age, and the recombinant 10 µg hepatitis B vaccine at 0, 6 and 14 weeks of age.
Group B: 212 subjects will receive the PENTAXIM™ and the recombinant 10 µg hepatitis B vaccines at 6, 10 and 14 weeks of age.
All infants included in the study will receive a booster dose of PENTAXIM™ vaccine at 18-19 months of age.
Age
0–1
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Informed consent signed by one or both parent(s) and/or by a legally accepted representative prior to the first study intervention
Healthy male or female newborn
Age ranging from birth to 48 hours of life (included)
Birth weight \>2.5 kg and gestational age \>37 weeks
Born to HBs antigen-negative mother
You may not be if
Known previous therapy of the mother with cadaveric pituitary derived human growth hormone
Infant presently enrolled or scheduled to be enrolled in another clinical trial
Infant with moderate or severe illness, mainly infectious diseases
Infant with fever (rectal temperature \> 38°C or axillary temperature \> 37.5°C)
Infant with severe congenital defects or abnormalities
Uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
Known immunological deficiency (including a known HIV seropositive mother)
Administration of vaccine since birth (other than BCG)
Previous or planned administration of immunosuppressive therapy, immunoglobulins and /or any blood-derived products (inhaled and topical corticoids are allowed)